Durability of humoral immune responses to rubella following MMR vaccination

While administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults. In this longitudinal...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 38; no. 51; pp. 8185 - 8193
Main Authors Crooke, Stephen N., Riggenbach, Marguerite M., Ovsyannikova, Inna G., Warner, Nathaniel D., Chen, Min-Hsin, Hao, Lijuan, Icenogle, Joseph P., Poland, Gregory A., Kennedy, Richard B.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 03.12.2020
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:While administration of the measles-mumps-rubella (MMR-II®) vaccine has been effective at preventing rubella infection in the United States, the durability of humoral immunity to the rubella component of MMR vaccine has not been widely studied among older adolescents and adults. In this longitudinal study, we sought to assess the durability of rubella virus (RV)-specific humoral immunity in a healthy population (n = 98) of adolescents and young adults at two timepoints: ~7 and ~17 years after two doses of MMR-II® vaccination. Levels of circulating antibodies specific to RV were measured by ELISA and an immune-colorimetric neutralization assay. RV-specific memory B cell responses were also measured by ELISpot. Rubella-specific IgG antibody titers, neutralizing antibody titers, and memory B cell responses declined with increasing time since vaccination; however, these decreases were relatively moderate. Memory B cell responses exhibited a greater decline in men compared to women. Collectively, rubella-specific humoral immunity declines following vaccination, although subjects’ antibody titers remain well above the currently recognized threshold for protective immunity. Clinical correlates of protection based on neutralizing antibody titer and memory B cell ELISpot response should be defined.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0264-410X
1873-2518
1873-2518
DOI:10.1016/j.vaccine.2020.10.076